CSL stock secures a rare disease deal worth up to US$1.6 billion

CSL stock (ISIN AU000000CSL8) was last at AUD 181.99 on the ASX on October 7, 2026, up AUD 3.31 or 1.85 percent from the prior close. The biotechnology group has also committed US$355 million upfront to a rare disease partnership, giving the recovery story a new pipeline angle.

Rare disease deal adds a new growth bet

According to CSL on October 5, 2026, CSL and Alentis Therapeutics agreed to develop and commercialize lixudebart for rare kidney and liver diseases. Alentis can receive up to US$1.2 billion in commercial milestones, while global profits will be shared between the companies.

The agreement gives CSL exposure to three potential disease applications, including focal segmental glomerulosclerosis and primary sclerosing cholangitis. Its structure places development funding with CSL, so the opportunity brings both pipeline potential and execution costs before any commercial return.

FY2026 results show the reset

CSL's investor information identifies FY2026 as the year ended June 30, 2026, with the full-year results webcast held on August 18, 2026. The Motley Fool Australia reported FY2026 revenue of US$15.8 billion and net profit after tax of US$2.6 billion, while the company separately reported a statutory net loss of US$2.58 billion in the same fiscal year.

Simply Wall St described the FY2026 result as revenue of US$15.8 billion, up 1.5 percent from FY2025, against a US$2.58 billion net loss. The contrast matters because the headline loss reflects impairment and restructuring effects, while revenue shows the operating base that management must rebuild.

Analyst target stays near the price

The Motley Fool Australia reported that 11 of 19 TradingView analysts rated CSL Buy or Strong Buy, with an average target of AUD 185.96. That target lies 2.2 percent above the AUD 181.99 price, leaving the consensus close to the market quotation rather than pointing to a wide valuation gap.

The market value was AUD 87.2 billion on October 7, 2026. The stock remained AUD 40.48 below its 52-week high of AUD 222.47 and AUD 91.99 above its 52-week low of AUD 90.00, placing the current quotation well inside its annual trading range.

CSL stock holds above AUD 180

CSL stock was last at AUD 181.99 on the ASX on October 7, 2026, with volume of 1,392,708 shares. The combination of the Alentis commitment, the FY2026 loss and the near-market analyst target makes execution of the pipeline and earnings recovery the central valuation test.

More news and analyses on CSL stock